Spots Global Cancer Trial Database for stage iv cutaneous melanoma ajcc v6 and v7

Every month we try and update this database with for stage iv cutaneous melanoma ajcc v6 and v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT01708941	Recurrent Melan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Laboratory Biom... Recombinant Int...	18 Years -	National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma	NCT02581930	Metastatic Mela... Recurrent Cutan... Stage IV Cutane...	Ibrutinib Laboratory Biom... Pharmacogenomic... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	NCT02910700	Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib	18 Years -	M.D. Anderson Cancer Center
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	NCT03384836	Stage IIIC Cuta... Stage IV Cutane...	Laboratory Biom... Pembrolizumab Propranolol Hyd...	18 Years -	Roswell Park Cancer Institute
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery	NCT03325101	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Cryosurgery Pembrolizumab Pheresis Therapeutic Aut...	18 Years -	Mayo Clinic
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	NCT03384836	Stage IIIC Cuta... Stage IV Cutane...	Laboratory Biom... Pembrolizumab Propranolol Hyd...	18 Years -	Roswell Park Cancer Institute
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	NCT02965716	Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Pembrolizumab Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	NCT01274338	Melanoma of Unk... Recurrent Melan... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Quality-of-Life... Recombinant Int...	12 Years -	National Cancer Institute (NCI)
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer	NCT03050060	Metastatic Kidn... Recurrent Lung ... Stage IV Cutane... Stage IV Renal ... Stage IV Lung N...	Atezolizumab Hypofractionate... Laboratory Biom... Nelfinavir Mesy... Nivolumab Pembrolizumab	18 Years -	University of Washington
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery	NCT02158520	Metastatic Mela... Mucosal Melanom... Stage IV Cutane... Stage IV Uveal ... Unresectable Me...	Bevacizumab Ipilimumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Academic and Community Cancer Research United
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	NCT01274338	Melanoma of Unk... Recurrent Melan... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Quality-of-Life... Recombinant Int...	12 Years -	National Cancer Institute (NCI)
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery	NCT03325101	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Cryosurgery Pembrolizumab Pheresis Therapeutic Aut...	18 Years -	Mayo Clinic
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	NCT01727076	Head and Neck S... Recurrent Head ... Recurrent Non-S... Recurrent Renal... Recurrent Skin ... Stage III Renal... Stage IIIA Cuta... Stage IIIA Non-... Stage IIIB Cuta... Stage IIIB Non-... Stage IIIC Cuta... Stage IV Cutane... Stage IV Non-Sm... Stage IV Renal ...	Laboratory Biom... Pharmacological... Recombinant Hum...	19 Years -	National Cancer Institute (NCI)
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma	NCT03276832	Metastatic Mela... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Imiquimod Biopsy Pembrolizumab Computed Tomogr... Positron Emissi... Magnetic Resona...	18 Years -	Mayo Clinic
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT03021460	Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma	NCT02339571	Stage III Cutan... Stage IV Cutane...	Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Multigated Acqu... Nivolumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma	NCT01807182	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Metastatic Mela...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Therapeutic Tum...	18 Years -	Fred Hutchinson Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Dinaciclib in Treating Patients With Stage IV Melanoma	NCT00937937	Acral Lentigino... Cutaneous Nodul... Lentigo Maligna... Low-CSD Melanom... Mucosal Melanom... Recurrent Melan... Stage IV Cutane...	Dinaciclib	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	NCT01940809	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Dabrafenib Ipilimumab Laboratory Biom... Nivolumab Trametinib	18 Years -	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery	NCT00861913	Recurrent Melan... Stage IV Cutane...	Laboratory Biom... Pazopanib Hydro... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT01134614	Advanced Melano... Metastatic Mela... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ipilimumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery	NCT03325101	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Cryosurgery Pembrolizumab Pheresis Therapeutic Aut...	18 Years -	Mayo Clinic
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	NCT02965716	Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Pembrolizumab Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma	NCT01740557	Metastatic Mela... Stage III Cutan... Stage IV Cutane...	Aldesleukin CXCR2-transduce... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... NGFR-transduced... Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT01134614	Advanced Melano... Metastatic Mela... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ipilimumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT01950390	Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Bevacizumab Ipilimumab	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies	NCT01364051	Metastatic Mela... Refractory Mali... Stage IV Cutane... Unresectable Ma...	Cediranib Cediranib Malea... Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer	NCT01480154	Advanced Malign... Stage III Cutan... Stage III Prost... Stage III Renal... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Stage IV Prosta... Stage IV Renal ...	Akt Inhibitor M... Hydroxychloroqu...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma	NCT02500576	Metastatic Mela... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Pembrolizumab Quality-of-Life... Therapeutic Tum...	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: